State Street Corp Purchases 19,207 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)

State Street Corp lifted its position in Candel Therapeutics, Inc. (NASDAQ:CADL) by 4.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 492,005 shares of the company’s stock after buying an additional 19,207 shares during the period. State Street Corp’s holdings in Candel Therapeutics were worth $3,410,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Atom Investors LP purchased a new position in shares of Candel Therapeutics during the third quarter valued at approximately $103,000. MetLife Investment Management LLC purchased a new position in shares of Candel Therapeutics during the third quarter valued at approximately $87,000. FMR LLC purchased a new position in shares of Candel Therapeutics during the third quarter valued at approximately $46,000. Point72 DIFC Ltd purchased a new position in shares of Candel Therapeutics during the second quarter valued at approximately $31,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Candel Therapeutics during the second quarter valued at approximately $162,000. Institutional investors own 13.93% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $19.00 price objective (up from $11.00) on shares of Candel Therapeutics in a report on Wednesday, December 18th.

Insider Buying and Selling at Candel Therapeutics

In other news, Director Paul B. Manning purchased 1,250,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was acquired at an average cost of $6.00 per share, for a total transaction of $7,500,000.00. Following the completion of the transaction, the director now directly owns 1,303,752 shares in the company, valued at $7,822,512. This trade represents a 2,325.49 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $6.05, for a total transaction of $90,750.00. Following the completion of the transaction, the insider now owns 944,873 shares of the company’s stock, valued at approximately $5,716,481.65. The trade was a 1.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,127 shares of company stock valued at $349,911. Insiders own 41.60% of the company’s stock.

Candel Therapeutics Stock Down 10.4 %

Shares of CADL stock opened at $7.95 on Tuesday. Candel Therapeutics, Inc. has a 12 month low of $1.16 and a 12 month high of $14.60. The stock has a market cap of $258.18 million, a P/E ratio of -4.60 and a beta of -0.95. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 1.66. The company has a 50 day simple moving average of $5.75 and a two-hundred day simple moving average of $6.08.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.